(Q45763995)

15 December 2017

title

Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus (English)

1 reference

15 December 2017

1 reference

Zhou XJ

1

1 reference

15 December 2017

Squires K

2

1 reference

15 December 2017

Pan-Zhou XR

3

1 reference

15 December 2017

Bernhard S

4

1 reference

15 December 2017

Agrofoglio L

5

1 reference

15 December 2017

Kirk M

6

1 reference

15 December 2017

Duchin KL

7

1 reference

15 December 2017

Sommadossi JP

8

1 reference

15 December 2017

publication date

1 March 1997

1 reference

15 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

15 December 2017

volume

37

1 reference

15 December 2017

issue

3

1 reference

15 December 2017

page(s)

201-213

1 reference

15 December 2017

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Nucleoside analogs: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Nucleotide dimers suppress HIV expression in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

Clinical pharmacokinetics of nucleoside antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1997.TB04782.X

10.1002/J.1552-4604.1997.TB04782.X

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

PubMed ID

9089422

1 reference

15 December 2017